This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stocks Under $10: Not Right at Rite Aid

Editor's Desk: We're launching Stocks Under $10, a new stock picking email alert service, that we don't want you to miss. Our inhouse research team is building a portfolio of stocks that are priced under $10 and will alert you to every trade they make and why. But that's not all: Our investment team will also issue alerts of stocks under $10 that should be avoided. Stocks Under $10 is normally $299.95 for an annual subscription. If you sign up before June 30, you can pick up an annual subscription for $249.95. For our subscribers to Action Alerts Plus, RealMoney and our premium newsletters, you can save $100 off an annual subscription through June 30 ... just $199.95.

A sample alert appears below. Act now to lock in your savings. Click here for a free trial.

Sometimes stocks stay in the single digits for so long that they become tempting buys. But you should curb the urge to buy long enough to do some careful research. Sometimes a low stock price creates opportunity, but more often than not, the stock is down because the market is pricing in realities that have yet to surface.

The latter appears to be what's happening with the country's third largest drug-store chain, Rite Aid (RAD - Get Report). The retailer has a colorful history of corrupt insiders and shady accounting and it now finds itself trying to generate sustainable growth following a round of industry consolidation.

Rite Aid shares rallied 33% over the past year but have slid 26% in 2004 since hitting their December highs. Investors had speculated the company could be the next takeover target after J.C. Penney's Eckerd division was sold to CVS (CVS - Get Report) and a Canadian drug store chain, and Duane Reade (DRD - Get Report) was bought out by a group of private investors.

An acquirer has yet to come calling for Rite Aid, and with investors focused solely on the company's business prospects, the future does not look as bright as it once did.

In all fairness, management has tried to improve the business, but has fallen way short of its competitors. Rite Aid's total sales grew 5.1% in fiscal 2004, up from 4.1% top-line growth in fiscal 2003. Compare this to CVS, where sales increased 10% in 2003, and WalGreen (WAG), which reported a sales increase of 13% for the same period, and the differences in growth are obvious. One-time events like the grocery strike in California and the strongest flu season in years contributed to Rite Aid's sales increase, and the company did say it managed to hold on to a large share of the business it grabbed from the strike.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CVS $101.25 -1.40%
DRD $4.97 8.75%
JCP $9.66 0.31%
RAD $8.04 -0.49%
AAPL $95.03 -2.90%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs